MDXG Stock Overview
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MiMedx Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.86 |
| 52 Week High | US$8.60 |
| 52 Week Low | US$2.43 |
| Beta | 1.66 |
| 1 Month Change | 15.25% |
| 3 Month Change | 2.34% |
| 1 Year Change | 152.73% |
| 3 Year Change | 30.56% |
| 5 Year Change | 410.39% |
| Change since IPO | 54.12% |
Recent News & Updates
Recent updates
Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08
Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
Sep 12MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range
Sep 06Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?
Apr 12Is MiMedx Group (NASDAQ:MDXG) A Risky Investment?
Nov 30Mimedx's Epifix secures regulatory approval in Japan
Jun 08US$18.00: That's What Analysts Think MiMedx Group, Inc. (NASDAQ:MDXG) Is Worth After Its Latest Results
May 01Is MiMedx Group (NASDAQ:MDXG) Weighed On By Its Debt Load?
Apr 19Did You Miss MiMedx Group's (NASDAQ:MDXG) 41% Share Price Gain?
Feb 25Activist investor discloses stake in MiMedx and suggests company to consider strategic alternatives
Jan 13Shareholder Returns
| MDXG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.4% | 4.1% | 0.6% |
| 1Y | 152.7% | -4.8% | 14.6% |
Return vs Industry: MDXG exceeded the US Biotechs industry which returned -5.8% over the past year.
Return vs Market: MDXG exceeded the US Market which returned 13.6% over the past year.
Price Volatility
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MDXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MDXG's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 867 | Joe Capper | https://www.mimedx.com |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
MiMedx Group, Inc. Fundamentals Summary
| MDXG fundamental statistics | |
|---|---|
| Market Cap | US$929.70m |
| Earnings (TTM) | -US$2.54m |
| Revenue (TTM) | US$309.02m |
3.0x
P/S Ratio-359.6x
P/E RatioIs MDXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXG income statement (TTM) | |
|---|---|
| Revenue | US$309.02m |
| Cost of Revenue | US$55.16m |
| Gross Profit | US$253.86m |
| Other Expenses | US$256.40m |
| Earnings | -US$2.54m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 82.15% |
| Net Profit Margin | -0.82% |
| Debt/Equity Ratio | 52.2% |
How did MDXG perform over the long term?
See historical performance and comparison